Actoxumab
Clostridium difficile toxin A | |
|---|---|
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6476H10000N1740O2010S45 |
| Molar mass | 145836.11 g·mol−1 |
Actoxumab is a human
Clostridium difficile infection.[1]
This drug, along with
Merck & Co., Inc. for further development and commercialization.[3]
A study compared it with bezlotoxumab (that targets CD toxin-B) and found Actoxumab less effective.[4]
References
- ^ "Statement On A Nonproprietary Name Adopted By The USAN Council - Actoxumab" (PDF). American Medical Association.
- PMID 20089970.
- ^ "Merck & Co., Inc., Medarex, Inc. and Massachusetts Biologic Laboratories Sign Exclusive Licensing Agreement for Investigational Monoclonal Antibody Combination for Clostridium Difficile Infection". Press Release. Merck Sharp & Dohme Corp.
- ^ New treatment for C.diff infections reduces recurrences by 40%, study finds
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |